Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Russo

Internal Medicine Greensboro, NC Medical Doctor

NPI 1215957303 CMS profile 191695

2703 Henry St, Greensboro, NC 27405

Open in the dashboard

General payments

$8,146

515 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Russo of Greensboro, NC is reported in the CMS Open Payments database as having received $8,146 across 515 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $887 46
2024 General $1,530 77
2023 General $1,548 97
2022 General $1,629 106
2021 General $553 41
2020 General $623 47
2019 General $1,377 101

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Russo
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to John Russo were reported at $887. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year John Russo Internal Medicine median Middle half National median
2019 $1,377 $159 $48–$570 $163
2020 $623 $119 $33–$402 $114
2021 $553 $135 $37–$521 $132
2022 $1,629 $141 $42–$496 $149
2023 $1,548 $149 $45–$519 $160
2024 $1,530 $154 $47–$537 $164
2025 $887 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $747 45 payments
  2. Amgen Inc. $693 52 payments
  3. Lilly USA, LLC $645 43 payments
  4. GlaxoSmithKline, LLC. $436 30 payments
  5. Novartis Pharmaceuticals Corporation $377 24 payments
  6. Pfizer Inc. $377 28 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $364 23 payments
  8. Sanofi-Aventis U.S. LLC $362 21 payments
  9. Radius Health, Inc. $289 17 payments
  10. Astellas Pharma US Inc $257 19 payments
  11. Other $3,599 213 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,146 515 payments
Products named General payments · program years 2019–2025
  1. MOUNJARO $346 21 payments
  2. UBRELVY $344 20 payments
  3. Repatha $326 23 payments
  4. Prolia $264 21 payments
  5. EVENITY $264 21 payments
  6. TRELEGY ELLIPTA $252 17 payments
  7. ENTRESTO $210 14 payments
  8. JARDIANCE $210 15 payments
  9. TZIELD $205 10 payments
  10. QULIPTA $198 11 payments
  11. Other $8,246 509 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 130 drugs

Part D claims

7,777

Median for Internal Medicine: 777

Drug cost

$682,155

Median for Internal Medicine: $73,373

Branded share of claims

18.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 148 $159,303
Eliquis Apixaban Brand 50 $59,007
Ozempic Semaglutide Brand 37 $54,974
Xarelto Rivaroxaban Brand 55 $52,131
Mounjaro Tirzepatide Brand 30 $42,977
Trulicity Dulaglutide Brand 16 $30,158
Farxiga Dapagliflozin Propanediol Brand 22 $23,802
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 11 $22,516
Synthroid Levothyroxine Sodium Brand 182 $19,097
Januvia Sitagliptin Phosphate Brand 18 $18,383

The 10 drugs with the highest cost, of 130 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$105,515

Of which drugs: $17,634

Medicare patients

203

Average age 78

Services billed

2,840

115 women, 88 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 59%
Ischemic heart disease 31%
Chronic kidney disease 27%
Depression 22%
Diabetes 21%
Cancer 20%
Osteoporosis 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 37 37 $10,706
Influenza vaccine, trivalent derived from recombinant dna 90673 Office 82 82 $6,546

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 36 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $118
$118 30 —
TZIELD
  • SANOFI-AVENTIS U.S. LLC $107
$107 — —
Wegovy
  • Novo Nordisk Inc $92
$92 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $46
  • Lilly USA, LLC $42
$87 148 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $63
$63 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 36 with Patron

Records

515 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record